The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy

HIV Medicine

Volumn 12, Issue 1, 2011, Pages 31-39

  Cooper, D A ^a   Cordery, D V ^a   Reiss, P ^b   Henry, K ^c   Nelson, M ^d   O'Hearn, M ^e   Reynes, J ^f   Arasteh K ^g   Chung, J ^h   Rowell, L ⁱ   Guimaraes, D ^h   Bertasso, A ^h  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f GUI DE CHAULIAC HOSPITAL   (France)

^g Vivantes Auguste Viktoria Klinikum   (Germany)

^h HOFFMANN LA ROCHE INC   (United States)

ⁱ ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Antiretroviral therapy; Enfuvirtide; HIV fusion inhibitor; Lipodystrophy

Indexed keywords

C PEPTIDE; ENFUVIRTIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NAUSEA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; SUBCUTANEOUS FAT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; BODY WEIGHT; DYSLIPIDEMIAS; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; TOMOGRAPHY, X-RAY COMPUTED; WAIST CIRCUMFERENCE; WAIST-HIP RATIO; YOUNG ADULT;

EID: 78650089513     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00845.x     Document Type: Article

References (23)

1. Schneider MF, Gange SJ, Williams CM et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS (London, UK) 2005; 19: 2009-2018.
2. Lichtenstein KA, Ward DJ, Moorman AC et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS (London, UK) 2001; 15: 1389-1398.
3. Miller J, Carr A, Emery S et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003; 4: 293-301.
4. Bacchetti P, Gripshover B, Grunfeld C et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40: 121-131.
5. Wand H, Law MG, Law I, Emery S, Cooper DA, Carr A. Increase in limb fat after nucleoside analogue cessation is not associated with decreased visceral fat and has different risk factors. Antiviral Ther 2005; 10: L5.
6. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-2099.
7. Duran S, Saves M, Spire B et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS (London, UK) 2001; 15: 2441-2444.
8. Burchfiel CM, Laws A, Benfante R et al. Combined effects of HDL cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease. Circulation 1995; 92: 1430-1436.
9. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation 2004; 109: III15-III19.
10. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrobial Chemother 2004; 53: 10-14.
11. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (London, UK) 1998; 12: F51-F58.
12. Domingo P, Labarga P, Palacios R et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS (London, UK) 2004; 18: 1475-1478.
13. Saves M, Raffi F, Capeau J et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 1396-1405.
14. Van Der Valk M, Gisolf EH, Reiss P et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS (London, UK) 2001; 15: 847-855.
15. Woerle HJ, Mariuz PR, Meyer C et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003; 52: 918-925.
16. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
17. Zhang X, Nieforth K, Lang JM et al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Therapeut 2002; 72: 10-19.
18. Nelson M, Arasteh K, Clotet B et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40: 404-412.
19. Trottier B, Walmsley S, Reynes J et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005; 40: 413-421.
20. Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-2185.
21. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-2195.
22. AIDS Clinical Trials Group. Table for Grading Severity of Adult Adverse Experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases, 1996.
23. Dwyer DE, Workman C, Hales G, Amin J, Cooper D, Miller J. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study. Antiviral Ther 2006; 11: 409-419.